npj Breast Cancer

Papers
(The H4-Index of npj Breast Cancer is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer351
Triple negative breast cancer: Pitfalls and progress184
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now146
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group126
Immunotherapy in breast cancer: an overview of current strategies and perspectives117
Evolution of HER2-low expression from primary to recurrent breast cancer113
Connected-UNets: a deep learning architecture for breast mass segmentation78
Immunotherapy for early triple negative breast cancer: research agenda for the next decade77
Large language model (ChatGPT) as a support tool for breast tumor board77
Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer64
PARP inhibition in breast cancer: progress made and future hopes62
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment58
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer55
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy50
The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment47
Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma45
Circulating tRNA-derived small RNAs (tsRNAs) signature for the diagnosis and prognosis of breast cancer44
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer42
Dynamic contrast-enhanced breast MRI features correlate with invasive breast cancer angiogenesis41
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors40
An emerging generation of endocrine therapies in breast cancer: a clinical perspective40
Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL40
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer39
Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies38
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer38
Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort37
Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer35
Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge35
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer35
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups34
IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer33
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis33
Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation32
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study32
A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes32
0.033890962600708